Laxmi Organic Q3 FY26 Earnings Call Transcript Released
Laxmi Organic Industries held an investor call on January 30, 2026, discussing Q3 FY26 performance. Revenue decreased 9% YoY with EBITDA down 33% to ₹50 crore. A ₹40.7 crore litigation settlement gain was recorded. Dahej Phase 2 capex of ₹710 crore is on track for Q4 FY26 completion. Management sees stabilization in acetic acid prices and improved ethyl acetate spreads.
The announcement details the company's performance, strategic initiatives, and future outlook. Key aspects include financial performance, capacity expansions (Dahej Phase 2), and feedstock price dynamics, which have a medium-term impact on the company's operations and profitability.
The company released a transcript of an investor call discussing Q3 FY26 results. While there are positive developments like the Dahej facility progress and expected stabilization in feedstock prices, the financial results showed a decline in revenue and EBITDA. The sentiment is neutral as it reflects a mix of challenges and forward-looking strategies.
Laxmi Organic Industries Limited held an investor and analyst meet on January 30, 2026, to discuss performance for the quarter ended December 31, 2025. The company released the transcript of this conference call.
During the call, management discussed global chemical industry challenges, including cost optimization and supply chain restructuring. Demand signals from key segments like packaging, inks, and adhesives remained stable, while agrochemicals were moderate, and paints & coatings were weak to moderate. Pharmaceuticals demand was stable.
Feedstock prices, particularly acetic acid, saw deflationary trends in prior periods but showed signs of reversal in December 2025. The company's Specialties business was impacted by market price moderation, a one-time campaign product in the previous year, and the phase-out of an agrochemical intermediate. In the Essentials segment, ethyl acetate spreads remained subdued, with a focus on volume-driven profitable growth.
New capacities are coming up in both Specialties and Essentials segments. The Phase 1 of the Dahej facility is operational, and Phase 2 is on track for completion by the end of Q4 FY26. The fluoro intermediates operation at Lote remains on track.
Financials for the quarter showed a revenue decrease of approximately 9% year-on-year, with EBITDA down 33% and PAT at ₹25 crores. This was attributed to pressure in ethyl acetate spreads, product mix differences, and incremental costs from Lote and Dahej facilities. The results also included a one-time gain of ₹407 million from a favorable litigation settlement for wheeling and transmission charges.
Management expressed optimism about the stabilization of acetic acid prices and improved ethyl acetate spreads from Q4 FY26 onwards. The Dahej Phase 2 capex of ₹710 crores is expected to see mechanical completions by the end of Q4 FY26, with ramp-up and customer qualification expected through FY27 and FY28.
Regarding the Specialties segment, margins were impacted by the agro product phase-out and feedstock moderation. The company aims to leverage its diketene derivative expertise and new capacities at Dahej to drive growth. The fluorination business is on track to achieve its targeted top line of ₹70-80 crores in FY26.
Laxmi Organic affirmed that its Lote facility operates in compliance with all applicable Indian requirements, with no discharge of hazardous effluent into the environment. The company is focusing on self-help measures including productivity, commercial and execution excellence, cost discipline, and new product development.
What to do with a filing like this
Laxmi Organic Industries Limited filed this with the NSE as a statutory disclosure, categorised under other investor communications. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laxmi Organic Industries Limited. Read the original for the full detail.